Changes in the Molecular Structure of the Brain in Bipolar Disorder: Findings using Human Postmortem Brain Tissue

2002 ◽  
Vol 3 (3) ◽  
pp. 125-132 ◽  
Author(s):  
Brian Dean
2002 ◽  
Vol 16 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Ronald W. H. Verwer ◽  
Wim T. J. M. C. Hermens ◽  
Paul A. Dijkhuizen ◽  
Olivier Ter Brake ◽  
Robert E. Baker ◽  
...  

2008 ◽  
Vol 20 (1) ◽  
pp. 67-76 ◽  
Author(s):  
Stefan Lorenzl ◽  
Katharina Büerger ◽  
Harald Hampel ◽  
M. Flint Beal

ABSTRACTBackground: Matrix metalloproteinases (MMPs) are elevated in the brain tissue of patients with dementia and may play a role in the pathophysiology of dementia. MMP-9 and tissue inhibitors of MMPs (TIMPs) are elevated in postmortem brain tissue of patients with Alzheimer's disease (AD). In a previous study we showed that circulating levels of MMP-9 are elevated in AD patients. The aim of the present study was to examine circulating levels of MMP-1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in the plasma of patients with mild cognitive impairment (MCI), AD, vascular dementia (VaD), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD), to determine, whether plasma profiles of MMPs and TIMPs differ in various types of dementia.Methods: Gelatinolytic activity (MMP-2 and MMP-9) was measured in all plasma samples by zymography. Levels of MMP-2, MMP-9, MMP-1 as well as TIMP-1 and TIMP-2 were measured by ELISA.Results: We found constitutive expression of MMP-1, -2 and -9 as well as TIMP-1 and -2 in all the samples investigated. As shown previously, MMP-9 was significantly elevated in the plasma of AD patients (p = 0.004) as compared to controls and MCI patients. Plasma levels of TIMP-1 were significantly lower in VD samples as compared to all other groups. Levels of TIMP-2 were significantly lower in patients with FTD as compared to AD, VaD and MCI patients. There were no significant changes of MMP-1 and MMP-2 levels in the samples.Conclusion: These findings suggest that circulating levels of MMP-9, TIMP-1 and TIMP-2 and changes in the MMP/TIMP balance in plasma differ in various types of dementia.


Author(s):  
Rosalinda C. Roberts ◽  
Michael W. Vogel ◽  
Maarten de Rijk ◽  
Frank J. Peretti ◽  
Robert R. Conley ◽  
...  

Classical and modern neuroanatomical techniques are applied to an analysis of the neuroanatomical basis of schizophrenia using postmortem brain tissue from the Maryland Brain Collection. Techniques for Golgi staining of cell bodies and dendritic arbors, axonal tract tracing with the carbocyanine dye, DiI and ultrastructural analyses will be used to study brain tissue with postmortem times of less than 6 hours. Although these techniques are routinely used in animal models, they are rarely used for studying human brain tissue. These techniques will allow us to characterize neuronal architecture in normal and diseased brains.


2021 ◽  
Vol 13 (595) ◽  
pp. eaba7394
Author(s):  
Ari W. Schaler ◽  
Avery M. Runyan ◽  
Catherine L. Clelland ◽  
Eric J. Sydney ◽  
Stephanie L. Fowler ◽  
...  

Accumulation of pathological tau in synapses has been identified as an early event in Alzheimer’s disease (AD) and correlates with cognitive decline in patients with AD. Tau is a cytosolic axonal protein, but under disease conditions, tau accumulates in postsynaptic compartments and presynaptic terminals, due to missorting within neurons, transsynaptic transfer between neurons, or a failure of clearance pathways. Using subcellular fractionation of brain tissue from rTg4510 tau transgenic mice with tauopathy and human postmortem brain tissue from patients with AD, we found accumulation of seed-competent tau predominantly in postsynaptic compartments. Tau-mediated toxicity in postsynaptic compartments was exacerbated by impaired proteasome activity detected by measuring lysine-48 polyubiquitination of proteins targeted for proteasomal degradation. To combat the accumulation of tau and proteasome impairment in the postsynaptic compartments of rTg4510 mouse brain, we stimulated the pituitary adenylate cyclase–activating polypeptide (PACAP) type 1 receptor (PAC1R) with its ligand PACAP administered intracerebroventricularly to rTg4510 mice. We observed enhanced synaptic proteasome activity and reduced total tau in postsynaptic compartments in mouse brain after PACAP treatment. The clearance of tau from postsynaptic compartments correlated with attenuated tauopathy and improved cognitive performance of rTg4510 transgenic mice on two behavioral tests. These results suggest that activating PAC1R could prevent accumulation of aggregate-prone tau and indicate a potential therapeutic approach for AD and other tauopathies.


2009 ◽  
Vol 110 (5) ◽  
pp. 1400-1408 ◽  
Author(s):  
Edna Grünblatt ◽  
Camelia Maria Monoranu ◽  
Manuela Apfelbacher ◽  
Daniela Keller ◽  
Tanja M. Michel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document